Gulley JL - Search Results

1

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G. DiPaola RS, et al. Among authors: gulley jl. Eur Urol. 2015 Sep;68(3):365-71. doi: 10.1016/j.eururo.2014.12.010. Epub 2014 Dec 18. Eur Urol. 2015. PMID: 25533418 Free PMC article. Clinical Trial.

2

Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.

Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY. Zhu M, et al. Cancer Res. 2001 May 1;61(9):3725-34. Cancer Res. 2001. PMID: 11325845

3

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. von Mehren M, et al. Clin Cancer Res. 2001 May;7(5):1181-91. Clin Cancer Res. 2001. PMID: 11350882 Clinical Trial.

4

The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.

Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J. Tsang KY, et al. Cancer Res. 2001 Oct 15;61(20):7568-76. Cancer Res. 2001. PMID: 11606396

5

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

6

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Terasawa H, et al. Clin Cancer Res. 2002 Jan;8(1):41-53. Clin Cancer Res. 2002. PMID: 11801539

7

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Gulley J, et al. Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.

8

A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.

Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY. Arlen PM, et al. Among authors: gulley jl. J Immunol Methods. 2003 Aug;279(1-2):183-92. doi: 10.1016/s0022-1759(03)00185-6. J Immunol Methods. 2003. PMID: 12969559

9

Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.

Arlen PM, Gulley JL, Tsang KY, Schlom J. Arlen PM, et al. Among authors: gulley jl. Expert Rev Vaccines. 2003 Aug;2(4):483-93. doi: 10.1586/14760584.2.4.483. Expert Rev Vaccines. 2003. PMID: 14711334 Review.

10

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. Tsang KY, et al. Clin Cancer Res. 2004 Mar 15;10(6):2139-49. doi: 10.1158/1078-0432.ccr-1011-03. Clin Cancer Res. 2004. PMID: 15041735

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

386 results

Search Page

Filters